World

Inovio Pharmaceuticals, Inc. (AMEX: INO) – Inovio dives into provisional data for phase 1 coronaviruses; DNA Vaccine Shows 94% Response Rate

Inovio Pharmaceuticals Inc (NASDAQ: INO) Shares moved lower on Tuesday after the vaccine maker released interim Phase 1 data for the study evaluating its INO-4800 DNA vaccine against SARS-CoV-2, the virus that causes COVID-19. Safety readings, provisional efficacy of Phase 1 of Inovio: Announcing the results of the first two …

Read More »